Metastasis suppressor pathways - An evolving paradigm

Cancer Letters

Volumn 198, Issue 1, 2003, Pages 1-20

  Shevde, Lalita A ^a   Welch, Danny R ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anoikis; Apoptosis; BRMS1; Cancer; CD44; CRMP1; CRSP3; DRG 1; E cadherin; Genes; Invasion; KAI1; KISS1; Marker; Maspin; Metastasis; Metastin; MKK4; Multigene; Nm23; Prognosis; Proliferation; SSeCKS; Suppression; Target; Therapeutic; TIMPs; Tumor; Tumorigenesis; TXNIP

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CADHERIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 1; DEXAMETHASONE; GELSOLIN; GUANOSINE TRIPHOSPHATASE; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 4; PROTEIN; PROTEIN KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SRC SUPPRESSED C KINASE SUBSTRATE; THIOREDOXIN INTERACTING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

BRMS1 GENE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME ANALYSIS; DISEASE COURSE; DNA DETERMINATION; DRG 1 GENE; FUNCTIONAL ASSESSMENT; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENETIC ANALYSIS; HOST; HUMAN; KAI 1 GENE; KISS 1 GENE; METASTASIS; NON METASTATIC CLONE 23 GENE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SUPPRESSOR GENE; ANIMAL; BIOLOGICAL MODEL; GENETICS; MALE; MOUSE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MODELS, GENETIC; NEOPLASM METASTASIS;

EID: 0037980379     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00304-5     Document Type: Review

References (202)

1. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., Alitalo K. Metastasis: lymphangiogenesis and cancer metastasis. Nature Rev. Cancer. 2:2002;573-583.
2. Steeg P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nature Rev. Cancer. 3:2003;55-63.
3. Welch D.R., Tomasovic S.P. Implications of tumor progression on clinical oncology. Clin. Exptl. Metastasis. 3:1985;151-188.
4. Nowell P. The clonal evolution of tumor cell populations. Science. 194:1976;23-28.
5. Luria S.E., Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 28:1943;491-511.
6. Bernards R., Weinberg R.A. Metastasis genes: a progression puzzle. Nature (London). 418:2002;823.
7. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 347:2002;1593-1603.
8. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature (London). 411:2001;375-379.
9. Coussens L.M., Werb Z. Inflammation and cancer. Nature (London). 420:2002;860-867.
10. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer. 2:2002;161-174.
11. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1:1889;571-573.
12. Folberg R., Hendrix M.J.C., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156:2000;361-381.
13. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M.G., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J.C. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155:1999;739-752.
14. Jain R.K., Munn L.L., Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nature Rev. Cancer. 2:2002;266-276.
15. Kieda C., Paprocka M., Krawczenko A., Zalecki P., Dupuis P., Monsigny M., Radzikowski C., Dus D. New human microvascular endothelial cell lines with specific adhesion molecules phenotypes. Endothelium New York. 9:2002;247-261.
16. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Med. 8:2002;751-755.
17. Pasqualini R., Arap W., McDonald D.M. Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med. 8:2002;563-571.
18. Ruoslahti E. Specialization of tumour vasculature. Nature Rev. Cancer. 2:2002;83-90.
19. Youngs S.J., Ali S.A., Taub D.D., Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int. J. Cancer. 71:1997;257-266.
20. Nicolson G.L. Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells. Biochim. Biophys. Acta. 695:1982;113-176.
21. Müller A., Homey B., Soto H., Ge N.F., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature (London). 410:2001;50-56.
22. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62:2002;1832-1837.
23. Balkwill F. Chemokine biology in cancer. Seminars Immunol. 15:2003;49-55.
24. Chambers A.F., MacDonald I.C., Schmidt E.E., Koop S., Morris V.L., Khokha R., Groom A.C. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 14:1995;279-301.
25. Koop S., MacDonald I.C., Luzzi K., Schmidt E.E., Morris V.L., Grattan M., Khokha R., Chambers A.F., Groom A.C. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res. 55:1995;2520-2523.
26. Qiu H.M., Orr F.W., Jensen D., Wang H.H., McIntosh A.R., Hasinoff B.B., Nance D.M., Pylypas S., Qi K., Song C., Muschel R.J., Al Mehdi A.B. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am. J. Pathol. 162:2003;403-412.
27. Al Mehdi A.B., Tozawa K., Fisher A.B., Shientag L., Lee A., Muschel R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 6:2000;100-102.
28. Chambers A.F., Groom A.C., MacDonald I.C. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer. 2:2002;563-572.
29. Weiss L. Metastatic inefficiency. Adv. Cancer Res. 54:1990;159-211.
30. Weiss L. Concepts of metastasis. Cancer Metastasis Rev. 19:2000;219-234.
31. Fidler I.J. Selection of successive tumor lines for metastasis. Nature New Biol. 242:1973;148-149.
32. Holmgren L. Antiangiogenesis restricted tumor dormancy. Cancer Metastasis Rev. 15:1996;241-245.
33. Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., Chambers A.F., Groom A.C. Multistep nature of metastatic inefficiency - dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153:1998;865-873.
34. Yoshida B.A., Dubauskas Z., Chekmareva M.A., Zaucha M.M., Christiano T.R., Christiano A.P., Stadler W.M., Rinker-Schaeffer C.W. Identification and characterization of candidate prostate cancer metastasis-suppressor genes encoded on human chromosome 17. Cancer Res. 59:1999;5483-5487.
35. Naumov G.N., MacDonald I.C., Weinmeister P.M., Kerkvliet N., Nadkarni K.V., Wilson S.M., Morris V.L., Groom A.C., Chambers A.F. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62:2002;2162-2168.
36. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1:1995;149-153.
37. Wong C.W., Lee A., Shientag L., Yu J., Dong Y., Kao G., Al Mehdi A.B., Bernhard E.J., Muschel R.J. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 61:2001;333-338.
38. Cameron M.D., Schmidt E.E., Kerkvliet N., Nadkarni K.V., Morris V.L., Groom A.C., Chambers A.F., MacDonald I.C. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60:2000;2541-2546.
39. Chishima T., Yang M., Miyagi Y., Li L., Tan Y., Baranov E., Shimada H., Moossa A.R., Penman S., Hoffman R.M. Governing step of metastasis visualized in vitro. Proc. Natl Acad. Sci. 94:1997;11573-11576.
40. Hoffman R.M. Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques. 30:2001;1016-1020.
41. Harms J.F., Budgeon L.R., Christensen N.D., Welch D.R. Maintaining green fluorescent protein tissue fluorescence through bone decalcification and long-term storage. Biotechniques. 33:2002;1197-1200.
42. Harms J.F., Welch D.R. MDA-MB-435 human breast carcinoma metastasis to bone. Clin. Exptl Metastasis. 2003;. in press.
43. Welch D.R., Rinker-Schaeffer C.W. What defines a useful marker of metastasis in human cancer? J. Natl Cancer Inst. 91:1999;1351-1353.
44. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:2003;49-54.
45. Nishizaki T., Devries S., Chew K., Goodson W.H., Ljung B.M., Thor A., Waldman F.M. Genetic alterations in primary breast cancers and their metastases - direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer. 19:1997;267-272.
46. Nakao K., Shibusawa M., Ishihara A., Yoshizawa H., Tsunoda A., Kusano M., Kurose A., Makita T., Sasaki K. Genetic changes in colorectal carcinoma tumors with liver metastases analyzed by comparative genomic hybridization and DNA ploidy. Cancer. 91:2001;721-726.
47. Redon R., Muller D., Caulee K., Wanherdrick K., Abecassis J., Du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res. 61:2001;4122-4129.
48. Wu W.G., Tang X.M., Hu W., Lotan R., Hong W.K., Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin. Exptl Metastasis. 19:2002;319-326.
49. Nakayama T., Taback B., Turner R., Morton D.L., Hoon D.S.B. Molecular clonality of in-transit melanoma metastasis. Am. J. Pathol. 158:2001;1371-1378.
50. Massi D., Sardi I., Urso C., Franchi A., Borgognoni L., Salvador A., Giannini A., Reali U.M., Santucci M. Microsatellite analysis in cutaneous malignant melanoma. Melanoma Res. 12:2002;577-584.
51. Shih J.Y., Yang S.C., Hong T.M., Yuan A., Chen J.J., Yu C.J., Chang Y.L., Lee Y.C., Peck K., Wu C.W., Yang P.C. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J. Natl Cancer Inst. 93:2001;1392-1400.
52. Reifenberger J., Knobbe C.B., Wolter M., Blaschke B., Schulte K.W., Pietsch T., Ruzicka T., Reifenberger G. Molecular genetic analysis of malignant melanomas for aberrations of the Wnt signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer. 100:2002;549-556.
53. Goldberg S.F., Miele M.E., Hatta N., Takata M., Paquette-Straub C.A., Freedman L.P., Welch D.R. Melanoma metastasis suppression by chromosome 6: Evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res. 2003;63.
54. Gopalkrishnan R.V., Kang D.C., Fisher P.B. Molecular markers and determinants of prostate cancer metastasis. J. Cell Physiol. 189:2001;245-256.
55. Welch D.R., Wei L.L. Genetic and epigenetic regulation of human breast cancer progression and metastasis. Endocrine-related Cancer. 5:1998;155-197.
56. Yoshida B.A., Sokoloff M., Welch D.R., Rinker-Schaeffer C.W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Natl Cancer Inst. 92:2000;1717-1730.
57. Rinker-Schaeffer C.W., Welch D.R., Sokoloff M. Defining the biologic role of genes that regulate prostate cancer metastasis. Curr. Opin. Urol. 10:2001;397-401.
58. Luu H.H., Zagaja G.P., Dubauskas Z., Chen S.L., Smith R.C., Watabe K., Ichikawa Y., Ichikawa T., Davis E.M., Le Beau M.M., Rinker-Schaeffer C.W. Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Res. 58:1998;3561-3565.
59. Kauffman E.C., Robinson V.L., Stadler W.M., Sokoloff M.H., Rinker-Schaeffer C.W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169:2003;1122-1133.
60. Chekmareva M.A., Hollowell C.M.P., Smith R.C., Davis E.M., LeBeau M.M., Rinker-Schaeffer C.W. Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate. 33:1997;271-280.
61. Fidler I.J., Radinsky R. Genetic control of cancer metastasis. J. Natl Cancer Inst. 82:1990;166-168.
62. Welch D.R. Technical considerations for studying cancer metastasis in vivo. Clin. Exptl Metastasis. 15:1997;272-306.
63. Welch D.R., Goldberg S.F. Molecular mechanisms controlling human melanoma progression and metastasis. Pathobiology. 65:1997;311-330.
64. Welch D.R., Chen P., Miele M.E., McGary C.T., Bower J.M., Weissman B.E., Stanbridge E.J. Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene. 9:1994;255-262.
65. Miele M.E., de la Rosa A., Lee J.H., Hicks D.J., Dennis J.U., Steeg P.S., Welch D.R. Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (Nm23). Clin. Exptl Metastasis. 15:1997;259-265.
66. You J., Miele M.E., Dong C., Welch D.R. Suppression of human melanoma metastasis by introduction of chromosome 6 may be partially due to inhibition of motility, but not to inhibition of invasion. Biochem. Biophys. Res. Comm. 208:1995;476-484.
67. Goldberg S.F., Harms J.F., Quon K., Welch D.R. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin. Exptl Metastasis. 17:1999;601-607.
68. Lee J.-H., Miele M.E., Hicks D.J., Phillips K.K., Trent J.M., Weissman B.E., Welch D.R. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl Cancer Inst. 88:1996;1731-1737.
69. Miele M.E., Lee J.-H., Robertson G., Coleman A., McGary C.T., Fisher P.B., Lugo T.G., Welch D.R. Metastasis is suppressed in human melanoma cell line MelJuSo following introduction of chromosomes 1 or 6 but tumorigenicity and local invasiveness are unaffected. Proc. Am. Assoc. Cancer Res. 37:1996;527.
70. Phillips K.K., Welch D.R., Miele M.E., Lee J.-H., Wei L.L., Weissman B.E. Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Res. 56:1996;1222-1226.
71. Steeg P.S., Bevilacqua G., Kopper L., Thorqeirsson U.P., Talmadge J.E., Liotta L.A., Sobel M.E. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl Cancer Inst. 80:1988;200-204.
72. Salerno M., Ouatas T., Palmieri D., Steeg P.S. Inhibition of signal transduction by the nm23 metastasis suppressor: Possible mechanisms. Clin. Exptl Metastasis. 20:2003;3-10.
73. Lombardi D., Lacombe M.L., Paggi M.G. nm23: Unraveling its biological function in cell differentiation. J. Cell Physiol. 182:2000;144-149.
74. Otsuki Y., Tanaka M., Yoshii S., Kawazoe N., Nakaya K., Sugimura H. Tumor metastasis suppressor nm23H1 regulates Rac1 GTPase by interaction with Tiam1. Proc. Natl Acad. Sci. 98:2001;4385-4390.
75. Postel E.H., Berberich S.J., Flint S.J., Ferrone C.A. Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science. 261:1993;478-480.
76. Wagner P.D., Steeg P.S., Vu N.D. Two-component kinase-like activity of nm23 correlates with its motility-suppressing activity. Proc. Natl Acad. Sci. 94:1997;9000-9005.
77. Hartsough M.T., Morrison D.K., Salerno M., Palmieri D., Ouatas T., Mair M., Patrick J., Steeg P.S. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of ras via a histidine protein kinase pathway. J. Biol. Chem. 277:2002;32389-32399.
78. Steeg P.S., Palmieri D., Ouatas T., Salerno M. Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. Cancer Lett. 190:2003;1-12.
79. Hartsough M.T., Clare S.E., Mair M., Elkahloun A.G., Sgroi D., Osborne C.K., Clark G., Steeg P.S. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. 61:2001;2320-2327.
80. Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 112:2003;659-672.
81. chikawa T., Ichikawa Y., Dong J., Hawkins A.L., Griffin C.A., Isaacs W.B., Oshimura M., Barrett J.C., Isaacs J.T. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res. 52:1992;3486-3490.
82. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., Barrett J.C. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268:1995;884-886.
83. Quinn C.C., Gray G.E., Hockfield S. A family of proteins implicated in axon guidance and outgrowth. J. Neurobiol. 41:1999;158-164.
84. Dong J.T., Suzuki H., Pin S.S., Bova G.S., Schalken J.A., Isaacs W.B., Barrett J.C., Isaacs J.T. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 56:1996;4387-4390.
85. Yang X.H., Welch D.R., Phillips K.K., Weissman B.E., Wei L.L. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett. 119:1997;149-155.
86. Phillips K.K., White A.E., Hicks D.J., Welch D.R., Barrett J.C., Wei L.L., Weissman B.E. Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein. Molec. Carcinog. 21:1998;111-120.
87. Takaoka A., Hinoda Y., Sato S., Itoh F., Adachi M., Hareyama M., Imai K. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn. J. Cancer Res. 89:1998;397-404.
88. Takaoka A., Hinoda Y., Satoh S., Adachi Y., Itoh F., Adachi M., Imai K. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene. 16:1998;1443-1453.
89. Duriez C., Falette N., Cortes U., Moyret-Lalle C., Puisieux A. Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene. 19:2000;2461-2464.
90. Mashimo T., Watabe M., Hirota S., Hosobe S., Miura K., Tegtmeyer P.J., Rinker-Schaeffer C.W., Watabe K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl Acad. Sci. 95:1998;11307-11311.
91. Sekita N., Suzuki H., Ichikawa T., Kito H., Akakura K., Igarashi T., Nakayama T., Watanabe M., Shiraishi T., Toyota M., Yoshie O., Ito H. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn. J. Cancer Res. 92:2001;947-951.
92. Odintsova E., Sugiura T., Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr. Biol. 10:2000;1009-1012.
93. Delaguillaumie A., Lagaudriere-Gesbert C., Popoff M.R., Conjeaud H. Rho GTPases link cytoskeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes. J. Cell Sci. 115:2002;433-443.
94. Lynch H.T., Casey M.J., Lynch J., White T.E.K., Godwin A.K. Genetics and ovarian carcinoma. Sem. Oncol. 25:1998;265-280.
95. Lee J.-H., Welch D.R. Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display. Int. J. Cancer. 71:1997;1035-1044.
96. Lee J.-H., Welch D.R. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 57:1997;2384-2387.
97. Goldberg S.F., Miele M.E., Paquette C.A., Welch D.R. Identifying metastasis suppressor genes in human melanoma. Anticancer Res. 2001.
98. Kotani M., Detheux M., Vandenbogaerde A., Communi D., Vanderwinden J.M., Le Poul E., Brezillon S., Tyldesley R., Suarez-Huerta N., Vandeput F., Blanpain C., Schiffmann S.N., Vassart G., Parmentier M. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J. Biol. Chem. 276:2001;34631-34636.
99. Muir A.I., Chamberlain L., Elshourbagy N.A., Michalovich D., Moore D.J., Calamari A., Szekeres P.G., Sarau H.M., Chambers J.K., Murdock P., Steplewski K., Shabon U., Miller J.E., Middleton S.E., Darker J.G., Larminie C.G.C., Wilson S., Bergsma D.J., Emson P., Faull R., Philpott K.L., Harrison D.C. AXOR12: a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J. Biol. Chem. 276:2001;28969-28975.
100. Ohtaki T., Shintani Y., Honda S., Matsumoto H., Hori A., Kanehashi K., Torao Y., Kumano S., Takatsu Y., Matsuda Y., Ishibashi Y., Watanabe T., Asada M., Yamada T., Suenaga M., Kitada C., Usuki S., Kurokawa T., Onda H., Nishimura O., Fujino M. Metastasis suppressor gene KiSS1 encodes peptide ligand of a G-protein-coupled receptor. Nature (London). 411:2001;613-617.
101. Ringel M.D., Hardy E., Bernet V.J., Burch H.B., Schuppert F., Burman K.D., Saji M. Metastin receptor Is overexpressed in papillary thyroid cancer and activates MAP Kinase in thyroid cancer cells. J. Clin. Endocrin. Metab. 87:2002;2399.
102. Stafford L.J., Xia C.Z., Ma W.B., Cai Y., Liu M.Y. Identification and characterization of mouse metastasis-suppressor KiSS1 and its G-protein-coupled receptor. Cancer Res. 62:2002;5399-5404.
103. Yan C.H., Wang H., Boyd D.D. KiSS-1 represses 92 kDa type IV collagenase expression by down- regulating NFκB binding to the promoter as a consequence of IκB α-induced block of p65/p50 nuclear translocation. J. Biol. Chem. 276:2001;1164-1172.
104. Janneau J.L., Maldonado-Estrada J., Tachdjian G., Miran I., Motte N., Saulnier P., Sabourin J.C., Cote J.F., Simon B., Frydman R., Chaouat G., Bellet D. Transcriptional expression of genes involved in cell invasion and migration by normal and tumoral trophoblast cells. J. Clin. Endocrin. Metab. 87:2002;5336-5339.
105. Shirasaki F., Takata M., Hatta N., Takehara K. Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res. 61:2001;7422-7425.
106. Chen K.S., DeLuca H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim. Biophys. Acta. 1219:1994;26-32.
107. Nakamura H., Nakamura K., Yodoi J. Redox regulation of cellular activation. Ann. Rev. Immunol. 15:1997;351-369.
108. Nishiyama A., Matsui M., Iwata S., Hirota K., Masutani H., Nakamura H., Takagi Y., Sono H., Gon Y., Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem. 274:1999;21645-21650.
109. Yamanaka H., Maehira F., Oshiro M., Asato T., Yanagawa Y., Takei H., Nakashima Y. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem. Biophys. Res. Comm. 271:2000;796-800.
110. Saitoh T., Tanaka S., Koike T. Rapid induction and Ca(2+) influx-mediated suppression of vitamin D3 up- regulated protein 1 (VDUP1) mRNA in cerebellar granule neurons undergoing apoptosis. J. Neurochem. 78:2001;1267-1276.
111. Junn E., Han S.H., Im J.Y., Yang Y., Cho E.W., Um H.D., Kim D.K., Lee K.W., Han P.L., Rhee S.G., Choi I. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J. Immunol. 164:2000;6287-6295.
112. Butler L.M., Zhou X., Xu W.S., Scher H.I., Rifkind R.A., Marks P.A., Richon V.M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. 99:2002;11700-11705.
113. Naar A.M., Beaurang P.A., Zhou S., Abraham S., Solomon W., Tjian R. Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature (London). 398:1999;828-832.
114. Taatjes D.J., Naar A.M., Andel F. III, Nogales E., Tjian R. Structure, function, and activator-induced conformations of the CRSP coactivator. Science. 295:2002;1058-1062.
115. Ryu S., Zhou S., Ladurner A.G., Tjian R. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature (London). 397:1999;446-450.
116. Jiang Y.F., Goldberg I.D., Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 21:2002;2245-2252.
117. Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11:2001;S37-S43.
118. Giannelli G., Bergamini C., Marinosci F., Fransvea E., Quaranta M., Lupo L., Schiraldi O., Antonaci S. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer. 97:2002;425-431.
119. Ylisirnio S., Hoyhtya M., Makitaro R., Paaakko P., Risteli J., Kinnula V.L., Turpeenniemi-Hujanen T., Jukkola A. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin. Cancer Res. 7:2001;1633-1637.
120. Pellegrini P., Contasta I., Berghella A.M., Gargano E., Mammarella C., Adorno D. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer. Cancer Immunol. Immunother. 49:2000;388-394.
121. Ylisirnio S., Hoyhtya M., Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. 20:2000;1311-1316.
122. Blavier L., Henriet P., Imren S., DeClerck Y.A. Tissue inhibitors of matrix metalloproteinases in cancer. Ann. NY Acad. Sci. 878:1999;108-119.
123. Mareel M., Boterberg T., Noe V., van Hoorde L., Vermeulen S., Bruyneel E., Bracke M. E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J. Cell Physiol. 173:1997;271-274.
124. Vermeulen S.J., Bruyneel E.A., Bracke M.E., De Bruyne G.K., Vennekens K.M., Vleminckx K.L., Berx G.J., van Roy F.M., Mareel M.M. Transition from the noninvasive to the invasive phenotype and loss of α-catenin in human colon cancer cells. Cancer Res. 55:1995;4722-4728.
125. Frixen U.H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., Lochner D., Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 113:1991;173-185.
126. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (London). 392:1998;190-193.
127. Christofori G., Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 24:1999;73-76.
128. Beavon I.R.G. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur. J. Cancer. 36:2000;1607-1620.
129. Nakayama S., Sasaki A., Mese H., Alcalde R.E., Tsuji T., Matsumura T. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int. J. Cancer. 93:2001;667-673.
130. Jiang W.G. E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br. J. Surg. 83:1996;437-446.
131. Shiozaki H., Oka H., Inoue M., Tamura S., Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer. 77:1996;1605-1613.
132. Nam J.S., Ino Y., Sakamoto M., Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 8:2002;2430-2436.
133. Berx G., Cleton-Jansen A.M., Strumane K., De Leeuw W.J.F., Nollet F., Van Roy F., Cornelisse C. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 13:1996;1919-1925.
134. Cavallaro U., Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim. Biophys. Acta Rev. Cancer. 1552:2001;39-45.
135. Kashima T., Nakamura K., Kawaguchi J., Takanashi M., Ishida T., Aburatani H., Kudo A., Fukayama M., Grigoriadis A.E. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int. J. Cancer. 104:2003;147-154.
136. Nieman M.T., Prudoff R.S., Johnson K.R., Wheelock M.J. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J. Cell Biol. 147:1999;631-643.
137. Tran N.L., Nagle R.B., Cress A.E., Heimark R.L. N-Cadherin expression in human prostate carcinoma cell lines, an epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am. J. Pathol. 155:1999;787-798.
138. Pishvaian M.J., Feltes C.M., Thompson P., Bussemakers M.J., Schalken J.A., Byers S.W. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res. 59:1999;947-952.
139. Li G., Satyamoorthy K., Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61:2001;3819-3825.
140. Hazan R.B., Phillips G.R., Qiao R.F., Norton L., Aaronson S.A. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 148:2000;779-790.
141. Teng D.H.F., Perry W.L. III, Hogan J.K., Baumgard M., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 57:1997;4177-4182.
142. Yoshida B.A., Dubauskas Z., Chekmareva M.A., Christiano T.R., Stadler W.M., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 59:1999;5483-5487.
143. Kim H.L., Van der Griend D.J., Yang X., Benson D.A., Dubauskas Z., Yoshida B.A., Chekmareva M.A., Ichikawa Y., Sokoloff M.H., Zhan P., Karrison T., Lin A., Stadler W.M., Ichikawa T., Rubin M.A., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 61:2001;2833-2837.
144. Yamada S.D., Hickson J.A., Hrobowski Y., VanderGriend D.J., Benson D., Montag A., Karrison T., Huo D.Z., Rutgers J., Adams S., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 62:2002;6717-6723.
145. Seraj M.J., Samant R.S., Verderame M.F., Welch D.R. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60:2000;2764-2769.
146. Shevde L.A., Samant R.S., Goldberg S.F., Sikaneta T., Alessandrini A., Donahue H.J., Mauger D.T., Welch D.R. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp. Cell Res. 273:2002;229-239.
147. Samant R.S., Debies M.T., Shevde L.A., Verderame M.F., Welch D.R. Identification and characterization of murine ortholog (Brms1) of breast cancer metastasis suppressor 1 (BRMS1). Int. J. Cancer. 97:2002;15-20.
148. Samant R.S., Seraj M.J., Saunders M.M., Sakamaki T., Shevde L.A., Harms J.F., Leonard T.O., Goldberg S.F., Budgeon L.R., Meehan W.J., Winter C.R., Christensen N.D., Verderame M.F., Donahue H.J., Welch D.R. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin. Exptl Metastasis. 18:2001;683-693.
149. Saunders M.M., Seraj M.J., Li Z.Y., Zhou Z.Y., Winter C.R., Welch D.R., Donahue H.J. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res. 61:2001;1765-1767.
150. Li Z., Zhou Z., Saunders M.M., Casey G., Welch D.R., Donahue H.J. Connexin and osteopontin expression correlate with breast cancer metastatic potential. Proc. Am. Assoc. Cancer Res. 2001;42.
151. Seraj M.J., Harding M.A., Gildea J.J., Welch D.R., Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin. Exptl Metastasis. 18:2001;519-525.
152. Hunter K.W., Broman K.W., LeVoyer T., Lukes L., Cozma D., Debies M.T., Rouse J., Welch D.R. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res. 61:2001;8866-8872.
153. LeVoyer T., Lifsted T., Williams M., Hunter K. era of hope - Department of Defense Breast Cancer Research Program. era of hope - Department of Defense Breast Cancer Research Program. Vol. 2:2000;. p. 625.
154. Park Y.G., Lukes L., Yang H., Debies M.T., Samant R.S., Welch D.R., Lee M., Hunter K.W. Comparative sequence analysis in eight inbred strains of the metastasis modifier QTL candidate gene Brms1. Mamm. Genome. 13:2002;289-292.
155. Lin X., Tombler E., Nelson P.J., Ross M., Gelman I.H. A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J. Biol. Chem. 271:1996;28430-28438.
156. Gelman I.H. The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front. Biosci. 7:2002;d1782-d1797.
157. Nauert J.B., Klauck T.M., Langeberg L.K., Scott J.D. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr. Biol. 7:1997;52-62.
158. Nelson P.J., Gelman I.H. Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with culture confluency, cell cycle phase and serum response. Mol. Cell. Biochem. 175:1997;233-241.
159. Lin X., Nelson P., Gelman I.H. SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)→S progression by controlling the expression and cellular compartmentalization of cyclin D. Molec. Cell. Biol. 20:2000;7259-7272.
160. Xia W., Unger P., Miller L., Nelson J., Gelman I.H. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. 61:2001;5644-5651.
161. Boettner B., VanAelst L. The role of Rho GTPases in disease development. Gene. 286:2002;155-174.
162. Gildea J.J., Seraj M.J., Oxford G., Harding M.A., Hampton G.M., Moskaluk C.A., Frierson H.F., Conaway M.R., Theodorescu D. RhoGD12 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 62:2002;6418-6423.
163. van Belzen N., Dinjens W.N., Diesveld M.P., Groen N.A., van der Made A.C., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab. Invest. 77:1997;85-92.
164. Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., Lee S.W. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 58:1998;4439-4444.
165. Guan R.J., Ford H.L., Fu Y., Li Y., Shaw L.M., Pardee A.B. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 60:2000;749-755.
166. Bandyopadhyay S., Pai S.K., Gross S.C., Hirota S., Hosobe S., Miura K., Saito K., Coomes T., Hayashi S., Watabe M., Watabe K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003;63.
167. Agarwala K.L., Kokame K., Kato H., Miyata T. Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein. Biochem. Biophys. Res. Comm. 272:2000;641-647.
168. Motwani M., Sirotnak F.M., She Y., Commes T., Schwartz G.K. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res. 62:2002;3950-3955.
169. Castellani V., Rougon G. Control of semaphorin signaling. Curr. Opin. Neurobiol. 12:2002;532-541.
170. Dickson B.J. Molecular mechanisms of axon guidance. Science. 298:2002;1959-1964.
171. Goshima Y., Ito T., Sasaki Y., Nakamura F. Semaphorins as signals for cell repulsion and invasion. J. Clin. Invest. 109:2002;993-998.
172. Comoglio P.M., Trusolino L. Invasive growth: from development to metastasis. J. Clin. Invest. 109:2002;857-862.
173. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., Miyazaki T., Leonor N., Taniguchi T., Fujita T., Kanakura Y., Komiya S., Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature (London). 387:1997;921-924.
174. Fujita H., Okada F., Hamada J., Hosokawa M., Moriuchi T., Koya R.C., Kuzumaki N. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int. J. Cancer. 93:2001;773-780.
175. Tanaka M., Müllauer L., Ogiso Y., Fujita H., Moriya S., Furuuchi K., Harabayashi T., Shinohara N., Koyanagi T., Kuzumaki N. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res. 55:1995;3228-3232.
176. Sagawa N., Fujita H., Banno Y., Nozawa Y., Katoh H., Kuzumaki N. Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br. J. Cancer. 88:2003;606-612.
177. Zou Z., Anisowicz A., Hendrix M.J.C., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:1994;526-529.
178. Reddy K.B., McGowen R., Schuger L., Visscher D., Sheng S.J. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model. Oncogene. 20:2001;6538-6543.
179. Jiang N., Meng Y.H., Zhang S.L., Mensah-Osman E., Sheng S.J. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 21:2002;4089-4098.
180. Zhang M., Volpert O., Shi Y.H., Bouck N. Maspin is an angiogenesis inhibitor. Nature Med. 6:2000;196-199.
181. Futscher B.W., Oshiro M.M., Wozniak R.J., Holtan N., Hanigan C.L., Duan H., Domann F.E. Role for DNA methylation in the control of cell type-specific maspin expression. Nat. Genet. 31:2002;175-179.
182. Costello J.F., Vertino P.M. Methylation matters: a new spin on maspin. Nat. Genet. 31:2002;123-124.
183. Zou Z., Gao C., Nagaich A.K., Connell T., Saito S., Moul J.W., Seth P., Appella E., Srivastava S. p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem. 275:2000;6051-6054.
184. Hs1 expression is associated with the metastatic phenotype in breast cancer. Cancer Res. 60:2000;3359-3363.
185. Gao A.C., Lou W., Dong J.T., Isaacs J.T. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 57:1997;846-849.
186. Yu D.H., Qu C.K., Henegariu O., Lu X., Feng G.S. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem. 273:1998;21125-21131.
187. Chekmareva M.A., Kadkhodaian M.M., Hollowell C.M.P., Kim H., Yoshida B.A., Luu H.H., Stadler W.M., Rinker-Schaeffer C.W. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res. 58:1998;4963-4969.
188. Steeg P.S., Ouatas T., Halverson D., Palmieri D., Salerno M. Metastasis suppressor genes: Basic biology and potential clinical use. Clin. Breast Cancer. 2003;. in press.
189. Zimmer S.G., Graff J.R. The emerging role for the mRNA cap-binding protein, EIF-4E, in metastatic progression. Welch D.R. Cancer Metastasis: Biology and Treatment. 2002;257-278 Kluwer Academic Publishers, Dordrecht.
190. Graff J.R., Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exptl Metastasis. 20:2003;265-273.
191. Plass C., Soloway P.D. DNA methylation imprinting and cancer. Eur. J. Hum. Genet. 10:2002;6-16.
192. Plass C. Cancer epigenomics. Hum. Molec. Genet. 11:2002;2479-2488.
193. Imhof A., Becker P.B. Modifications of the histone N-terminal domains, evidence for an epigenetic code? Mol. Biotechnol. 17:2001;1-13.
194. Karpf A.R., Jones D.A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 21:2002;5496-5503.
195. Kelly W.K., O'Connor O.A., Marks P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs. 11:2002;1695-1713.
196. Elledge R.M., Lee W.H. Life and death by p53. BioEssays. 17:1995;923-930.
197. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., VanMeir E.G., Simons J.W., Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:2002;2478-2482.
198. Ouatas T., Halverson D., Steeg P.S. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor expression in metastatic human breast carcinoma cells via glucocorticoid receptor-dependent, transcriptional and post-transcriptional mechanisms: new uses for old compounds, Clin. Cancer Res. 2003;. in press.
199. Desprez P.Y., Lin C.Q., Thomasset N., Sympson C.J., Bissell M.J., Campisi J. Novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. Mol. Cell. Biol. 18:1998;4577-4588.
200. Singh J., Murata K., Itahana Y., Desprez P.Y. Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene. 21:2002;1812-1822.
201. Toh Y., Pencil S.D., Nicolson G.L. A novel candidate metastasis- associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines, cDNA cloning, expression, and protein analyses. J. Biol. Chem. 269:1994;22958-22963.
202. Nicolson G.L., Nawa A., Toh Y., Taniguchi S., Nishimori K., Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin. Exptl Metastasis. 20:2003;19-24.